Enhanced G2-M arrest by nuclear factor-κB-dependent p21waf1/cip1 induction

Molecular Cancer Research

Volumn 3, Issue 6, 2005, Pages 345-353

  Wuerzberger Davis, Shelly M ^a   Chang, Pei Yun ^a   Berchtold, Craig ^a   Miyamoto, Shigeki ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P21; PROTEIN P21 WAF1 CIP1; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; CAMPTOTHECIN; CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DOXORUBICIN; ENZYME INHIBITOR; ETOPOSIDE; NUCLEIC ACID SYNTHESIS INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER CELL; CELL CYCLE; CELL CYCLE G2 PHASE; CELL SURVIVAL; DNA DAMAGE; HUMAN; HUMAN CELL; IONIZING RADIATION; LEUKEMIA CELL; MITOSIS INHIBITION; MOLECULAR MECHANICS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN INDUCTION; RNA INTERFERENCE; TRANSCRIPTION REGULATION; APOPTOSIS; BREAST TUMOR; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; METABOLISM; MITOSIS; PATHOLOGY; RADIATION EXPOSURE; T LYMPHOCYTE; TIME; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BREAST NEOPLASMS; CAMPTOTHECIN; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOXORUBICIN; ENZYME INHIBITORS; ETOPOSIDE; FEMALE; FLOW CYTOMETRY; G2 PHASE; HUMANS; MITOSIS; NF-KAPPA B; NUCLEIC ACID SYNTHESIS INHIBITORS; RADIATION, IONIZING; RNA INTERFERENCE; T-LYMPHOCYTES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 21344435495     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-05-0028     Document Type: Article

References (49)

1. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S. Rel/NF-κB/IκB family: intimate tales of association and dissociation. Genes Dev 1995;9:2723-35.
2. Ghosh S, May MJ, Kopp EB. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-60.
3. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest 2001;107:241-6.
4. Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C. The prosurvival Bcl-2 homolog Bfl-I/AI is a direct transcriptional target of NF-κB that blocks TNFα-induced apoptosis. Genes Dev 1999;13:382-7.
5. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and C-IAP1 and C-IAP2 to suppress caspase-8 activation. Science 1998;281:1680-3.
6. Tang G, Minemoto Y, Dibling B, et al. Inhibition of JNK activation through NF-κB target genes. Nature 2001;414:313-7.
7. Grumont RJ, Rourke IJ, Gerondakis S. Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. Genes Dev 1999;13:400-11.
8. Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis C-IAP2 is under NF-κB control. Proc Natl Acad Sci U S A 1997;94:10057-62.
9. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol 2000;18:621-63.
10. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell 1994;78:773-85.
11. Traenckner EB, Wilk S, Baeuerle PA. A proteasome inhibitor prevents activation of NF-κB and stabilizes a newly phosphorylated form of IκB-α that is still bound to NF-κB. EMBO J 1994;13:5433-41.
12. Alkalay I, Yaron A, Hatzubai A, et al. In vivo stimulation of IκB phosphorylation is not sufficient to activate NF-κB. Mol Cell Biol 1995;15: 1294-301.
13. DiDonato J, Mercuric F, Karin M. Phosphorylation of IκBα precedes but is not sufficient for its dissociation from NF-κB. Mol Cell Biol 1995;15:1302-11.
14. Beg AA, Baltimore D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science 1996;274:782-4.
15. Doi TS, Marino MW, Takahashi T, et al. Absence of tumor necrosis factor rescues RelA-deficient mice from embryonic lethality. Proc Natl Acad Sci 1999; 96:2994-9.
16. Li Z-W, Chu W, Hu Y, et al. The IKKβ subunit of IκB kinase (IKK) is essential for nuclear factor κB activation and prevention of apoptosis. J Exp Med 1999;189:1839-45.
17. Rudolph D, Yen W-C, Wakeham A, et al. Severe liver degeneration and lack of NF-κB activation in NEMO/IKKβ-deficient mice. Genes Dev 2000;14:854-62.
18. Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-κB transcription factors. Oncogene 1999;18:6910-24.
19. Lin B, Williams-Skipp C, Tao Y, et al. NF-κB functions as both a proapoptotic and antiapoptotic regulatory factor within a single cell type. Cell Death Differ 1999;6:570-82.
20. Huang TT, Wuerzberger-Davis SM, Seufzer BJ, et al. NF-κB activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events. J Biol Chem 2000;275:9501-9.
21. Habraken Y, Piret B, Piette J. S phase dependence and involvement of NF-κB activating kinase to NF-κB activation by camptothecin. Biochem Pharmacol 2001;62:603-16.
22. Nakamura Y. Isolation of p53-target genes and their functional analysis. Cancer Sci 2004;95:7-11.
23. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
24. WAF1/Cip1: more than a break to the cell cycle? Biochim Biophys Acta 2000;1471:M43-56.
25. Li N, Karin M. Ionizing radiation and short wavelength UV activate NF-κB through two distinct mechanisms. Proc Natl Acad Sci U S A 1998;95:13012-7.
26. Lee SJ, Dimtchev A, Lavin MF, Dritschilo A, Jung M. A novel ionizing radiation-induced signaling pathway that activates the transcription factor NF-κB. Oncogene 1998;17:1821-6.
27. Wang C-Y, Mayo MW, Baldwin AS Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 1996;274:784-7.
28. Van Antwerp DJ, Verma IM. Signal-induced degradation of IκBα: association with NF-κB, the PEST sequence in IκBα are not required. Mol Cell Biol 1996;16:6037-45.
29. Lee H, Arsura M, Wu M, Duyao M, Buckler AJ, Sonenshein GE. Role of Rel-related factors in control of c-myc gene transcription in receptor-mediated apoptosis of the murine B cell WEHI 231 line. J Exp Med 1995;181:1169-77.
30. Chen X, Kandasamy K, Srivastava RK. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor κB in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Res 2003;63:1059-66.
31. 2-M arrest after DNA damage. J Biol Chem 2001; 276:42971-7.
32. Pakneshan P, Szyf M, Rabbani SA. Methylation and inhibition of expression of uPA by the RAS oncogene: divergence of growth control and invasion in breast cancer cells. Carcinogenesis 2005;26:557-64.
33. Karin M, Yamamoto Y, Wang QM. The IKK NF-κB system: a treasure trove for drug development. Nat Rev Drug Discov 2004;3:17-26.
34. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004; 432:316-23.
35. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 2001;15:2177-96.
36. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000;408:433-9.
37. Meyers M, Hwang A, Wagner MW, Boothman DA. Role of DNA mismatch repair in apoptotic responses to therapeutic agents. Environ Mol Mutagen 2004; 44:249-64.
38. 2-M checkpoint. Genes Dev 2000;14:1584-8.
39. waf1/cip1 promoter by Sp1. Cancer Res 2004;64:743-50.
40. 2 arrest in esophageal squamous cell carcinoma. J Surg Res 1999;81:6-10.
41. Hellin AC, Bentires-Alj M, Verlaet M, et al. Roles of nuclear factor-κB, p53, and p21/WAF1 in daunomycin-induced cell cycle arrest and apoptosis. J Pharmacol Exp Ther 2000;295:870-8.
42. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002;1:639-49.
43. Perkins ND, Felzien LK, Berts JC, Leung K, Beach DH, Nabel GJ. Regulation of NF-κB by cyclin-dependent kinases associated with the p300 coactivator. Science 1997;275:523-7.
44. Huang TT, Miyamoto S. Postrepression activation of NF-κB requires the amino-terminal nuclear export signal specific to IκBα. Mol Cell Biol 2001; 21:4737-47.
45. Miyamoto S, Seufzer BJ, Shumway SD. Novel IκBα proteolytic pathway in WEHI231 immature B cells. Mol Cell Biol 1998;18:19-29.
46. Huang TT, Feinberg SL, Suryanarayanan S, Miyamoto S. The zinc finger domain of NEMO is selectively required for NF-κB activation by UV radiation and topoisomerase inhibitors. Mol Cell Biol 2002;22:5813-25.
47. Wuerzberger SM, Pink JJ, Planchon SM, Byers KL, Bornmann WG, Boothman DA. Induction of apoptosis in MCF-7:WS8 breast cancer cells by p-lapachone. Cancer Res 1998;58:1876-85.
48. Huang TT, Kudo N, Yoshida M, Miyamoto S. A nuclear export signal in the N-terminal regulatory domain of IκBα controls cytoplasmic localization of inactive NF-κB/IκBα complexes. Proc Natl Acad Sci U S A 2000;97:1014-9.
49. Chu J, Bresnick EH. Evidence that C promoter-binding factor I binding is required for Notch-1 -mediated repression of activator protein-1. J Biol Chem 2004; 279:12337-45.